SCHEMBL3065005

SCHEMBL3065005

O=S(=O)(Cc1ccc(C(F)(F)F)cc1)c1ccc(S(=O)(=O)Nc2nccs2)cc1

nearest known ligand 0.81

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
SCN3A Q9NY46 6/20 0.81
ALDH1A1 P00352 3/20 0.55
LMNA P02545 2/20 0.55
KDM4E B2RXH2 1/20 0.55
CYP2C9 P11712 1/20 0.55
EDNRA P25101 1/20 0.55
SLC6A4 P31645 1/20 0.55
ADRA1A P35348 1/20 0.55
PRMT6 Q96LA8 1/20 0.55
TDP1 Q9NUW8 1/20 0.55
SMN1; SMN2 Q16637 1/20 0.55
PKM P14618 2/20 0.53
MEN1 O00255 1/20 0.52
KMT2A Q03164 1/20 0.52
CYP1A2 P05177 1/20 0.51
ATM Q13315 1/20 0.51
SCN9A Q15858 6/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3060426 0.90 SCN3A (1.00) SCN3AALDH1A1LMNAKDM4ECYP2C9
SCHEMBL3062720 0.89 SCN3A (0.90) SCN3AALDH1A1LMNAKDM4ECYP2C9
SCHEMBL3058171 0.88 SCN3A (0.64) SCN3AALDH1A1LMNAKDM4ECYP2C9
SCHEMBL3050459 0.84 SCN3A (0.65) SCN3AALDH1A1LMNAKDM4ECYP2C9
SCHEMBL13452602 0.82 SCN3A (1.00) SCN3AALDH1A1LMNAMEN1KMT2A
SCHEMBL3161085 0.81 SCN3A (0.81) SCN3AALDH1A1PKMMEN1KMT2A
SCHEMBL3068460 0.79 SCN3A (0.77) SCN3AALDH1A1LMNAKDM4ECYP2C9
SCHEMBL3164258 0.79 SCN3A (0.69) SCN3ATDP1MEN1KMT2A
SCHEMBL3055402 0.79 SCN3A (0.76) SCN3ASCN9A
SCHEMBL3060924 0.79 SCN3A (0.57) SCN3AEDNRATDP1MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140357685-A1 Sodium Channel Inhibitors ICAGEN INC (US) 2014-12-04 US disclosed
US-8853250-B2 Sodium channel inhibitors ICAGEN, INC. (US) 2014-10-07 US disclosed
EP-2175728-B1 SODIUM CHANNEL INHIBITORS ICAGEN INC (US) 2014-09-10 EP disclosed
US-20100267782-A1 SODIUM CHANNEL INHIBITORS ICAGEN, INC (US) 2010-10-21 US disclosed
EP-2175728-A1 SODIUM CHANNEL INHIBITORS Icagen, Inc. (US) 2010-04-21 EP disclosed
WO-2009012241-A1 SODIUM CHANNEL INHIBITORS ICAGEN, INC. (US) 2009-01-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140357685-A1 Sodium Channel Inhibitors TRPV1, SCN1A, SCN2A SCN3A 8/4885ALDH1A1 2837/4885LMNA 3041/4885
US-20100267782-A1 SODIUM CHANNEL INHIBITORS TRPV1, SCN1A, SCN2A SCN3A 8/4885ALDH1A1 2837/4885LMNA 3041/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.